BioMark Diagnostics Inc
SWB:20B
Net Margin
BioMark Diagnostics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CA |
B
|
BioMark Diagnostics Inc
CNSX:BUX
|
30.4m CAD |
-1 224%
|
|
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
633.6T EUR | N/A | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
180.1B USD |
5%
|
|
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
104.4B USD |
9%
|
|
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
84.5B Zac |
69%
|
|
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
52.9B USD |
-44%
|
|
| US |
|
Coupang Inc
F:788
|
46.7B EUR |
1%
|
|
| US |
C
|
Circle Internet Group Inc
NYSE:CRCL
|
39B USD |
9%
|
|
| CH |
G
|
Galderma Group AG
SIX:GALD
|
30.3B CHF |
8%
|
|
| ID |
|
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
614.6T IDR |
18%
|
|
| IN |
G
|
GTV Engineering Ltd
BSE:539479
|
3B INR |
11%
|
BioMark Diagnostics Inc
Glance View
BioMark Diagnostics, Inc. engages in development and commercialization of cancer diagnostic solutions to detect, monitor, and assess treatment for cancer. The company is headquartered in Richmond, British Columbia. The company went IPO on 2014-11-03. The Company’s cancer diagnostic solutions can help detect, monitor and assess treatment for cancer. Its cancer diagnostics technology platform leverages Omics and machine learning, which allows for early cancer detection. The firm is focused on bringing its cancer diagnostic kits and detection solution to commercialization standards. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. The firm has developed a liquid biopsy metabolic panel assay. This metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections. The capabilities include early stage I and II Lung Cancers using urine and plasma.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on BioMark Diagnostics Inc's most recent financial statements, the company has Net Margin of -1 223.7%.
You don't have any saved screeners yet